| Survival rates following expansion of the national pediatric antiretroviral treatment program, Thailand, 2000-2005 | MOAB101 |
| |
Time: 14:30
Presented by: Michelle McConnell
|
| |
| |
For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.
|
|
| High survival and treatment success sustained after up to three years of ART for children in Cambodia | MOAB102 |
| |
Time: 14:45
Presented by: Petros Isaakidis
|
| |
| |
For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.
|
|
| Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis | MOAB103 |
| |
Time: 15:00
Presented by: Ashraf Coovadia
|
| |
| |
For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.
|
|
| Virologic failure and second-line antiretroviral therapy (ART) in children in South Africa: the international epidemiologic databases to evaluate AIDS (IeDEA) Southern Africa collaboration | MOAB104 |
| |
Time: 15:15
Presented by: Mary-Ann Davies
|
| |
| |
For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.
|
|
| How well do the revised World Health Organisation weight-based dosing guidelines for lopinavir/ritonavir in infants and children correlate with body surface area-based dosing recommendations? | MOAB105 |
| |
Time: 15:30
Presented by: James Nuttall
|
| |
| |
For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.
|
|